Svenska

Elypta stärker sitt kommersiella fokus - välkomnar Dr. Hilja Ibert till styrelsen

Report this content

Elypta Strengthens Commercial Focus, Welcomes Dr. Hilja Ibert to Board of Directors

Stockholm, Sweden, April 7, 2025. Elypta, the Swedish company pioneering metabolism-based early cancer detection, is pleased to announce the appointment of Dr. Hilja Ibert to its Board of Directors. Hilja brings extensive leadership experience in the diagnostics industry and a strong track record of commercial success.

“Hilja’s deep expertise in commercializing diagnostics will be invaluable as we aim to launch our first diagnostic products next year,” says Elypta CEO Karl Bergman.

Dr. Ibert has over 30 years of experience in clinical diagnostics, having held senior positions at international companies, including Hologic, Becton Dickinson, and bioMérieux. She recently served as CEO and now chairs the Board of Gentian Diagnostics ASA, where she played a key role in the company’s growth and success. She is also a board member at Gradientech, a company specializing in ultra-rapid antibiotic susceptibility testing. Dr. Ibert holds a Ph.D. in Microbiology and a degree in Nutritional Sciences from the Rheinische Friedrich Wilhelms Universität of Bonn, Germany.

“I am excited to join Elypta at this pivotal moment as the company prepares to bring its diagnostic solutions to market, and I look forward to contributing to Elypta’s commercial success,” says Dr. Ibert.

“Hilja’s wealth of experience in commercializing diagnostics will be instrumental in ensuring maximal impact of Elypta’s technology and advancing our mission to prevent cancer mortality through early detection,” says Elypta chairman and founder, Jens Nielsen.

 

For more information, please contact:

Karl Bergman, CEO, info@elypta.com

About Elypta

Elypta is a Swedish cancer detection company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome) and algorithms trained to detect cancer-specific signatures. Elypta is advancing a broad study program across different cancers with the leading indications being early detection of recurrence in renal cell carcinoma and multi-cancer early detection. www.elypta.com

Prenumerera

Media

Media

Citat

Hiljas djupa expertis inom kommersialisering av diagnostiklösningar kommer att spela en nyckelroll när vi närmar oss lanseringen av våra första produkter nästa år
Elyptas VD Karl Bergman
Jag är glad över att nu ingå i Elyptas styrelse i detta avgörande läge för företaget när man förbereder sig för att ta sina diagnostiska lösningar till marknaden, och jag ser fram emot att bidra till Elyptas kommersiella framgång.
Dr. Hilja Ibert.
Hiljas stora erfarenhet av att kommersialisera diagnostik kommer att vara avgörande för att säkerställa maximal effekt av Elyptas teknologi och driva på vår mission att förhindra cancerdödlighet genom tidig upptäckt.
Elyptas styrelseordförande och grundare, Jens Nielsen.